Inclusion Criteria:

- Adult patients, >/=18 years of age

- Histologically confirmed adenocarcinoma of the stomach or gastro-esophageal junction
with advanced or metastatic disease, not amenable to curative therapy

- Measurable disease, according to the Response Evaluation Criteria in Solid Tumors
(RECIST)

- HER2 positive tumor (primary tumor or metastasis

- ECOG Performance status 0, 1 or 2

- Life expectancy of at least 3 months

Exclusion Criteria:

- Previous chemotherapy for advanced or metastatic disease less than 6 month before
study start

- Lack of physical integrity of the upper gastrointestinal tract or malabsorption
syndrome (patients with partial or total gastrectomy are allowed to participate in
the study)

- Patients with active (significant or uncontrolled) gastrointestinal bleeding

- Residual relevant toxicity resulting from previous chemotherapy

- Other malignancy within the last 5 years (except carcinoma in situ of the cervix, or
basal cell carcinoma)